Scarica l'app Stockscreener
7.42
0.95%
0.07
Precedente Chiudi:
$7.35
Aprire:
$7.795
Volume 24 ore:
2,530
Relative Volume:
0.48
Capitalizzazione di mercato:
$67.60M
Reddito:
$70,100
Utile/perdita netta:
$-9.67M
Rapporto P/E:
-6.446
EPS:
-1.1511
Flusso di cassa netto:
$-7.09M
1 W Prestazione:
-4.87%
1M Prestazione:
-23.98%
6M Prestazione:
-40.73%
1 anno Prestazione:
-41.53%
Intervallo 1D:
$7.358
$7.795
Intervallo di 1 settimana:
$7.10
$8.5905
Portata 52W:
$7.08
$18.40
Exozymes Inc Stock (EXOZ) Company Profile
Nome
Exozymes Inc
Settore
Industria
Telefono
(626) - 415 - 1488
Indirizzo
750 ROYAL OAKS DR, MONROVIA
Compare EXOZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
7.42 | 66.96M | 70,100 | -9.67M | -7.09M | -1.1511 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exozymes Inc Borsa (EXOZ) Ultime notizie
eXoZymes (EXOZ) Prices Public Offering of Units - GuruFocus
eXoZymes Announces Public Equity Offering to Fund Growth - TipRanks
eXoZymes Prices $18 Unit Equity Offering; MDB Capital Underwrites $5.33 Million Deal - TradingView
eXoZymes (NASDAQ: EXOZ) sells units in $5.3M underwritten offering - Stock Titan
eXoZymes prices $5.33M offering of units at $18/unit - scanx.trade
exozymes prices $5.3M public offering at $18 per unit - Investing.com
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants - ACCESS Newswire
AI enzyme firm eXoZymes prices $5.33M unit deal with resettable warrants - Stock Titan
eXoZymes (NASDAQ: EXOZ) sells 592,270 shares and 296,135 warrants in $18 units - Stock Titan
EXOZ Technical Analysis | Trend, Signals & Chart Patterns | EXOZYMES INC (NASDAQ:EXOZ) - ChartMill
eXoZymes (EXOZ) seeks to sell units of common stock and warrants in offering - Stock Titan
eXoZymes (EXOZ) to sell share-and-warrant units; MDB holds 47.8% - Stock Titan
eXoZymes Inc. (EXOZ) Surges 5.5% – Key Levels to Watch After the RallyCash Secured Put - newsline.com
eXoZymes Inc. (EXOZ) Climbs 3.13% as Biotech Stock Tests Key Resistance at $10.74Inside Day Breakout - The Legal Advocate
Number of shareholders of eXoZymes Inc. – NASDAQ:EXOZ - TradingView
EXOZYMES INC. 1Q 2026: Revenue $0 Net income $(2.37M) — 10-Q Summary - TradingView
EXoZymes, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
eXoZymes (NASDAQ: EXOZ) Q1 2026 loss deepens amid cash burn, planned raise - Stock Titan
TradingKey - TradingKey
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program - ACCESS Newswire
eXoZymes Prepares Investor Presentation for Proposed Public Offering - TipRanks
eXoZymes (EXOZ) files investor presentation for proposed securities offering - Stock Titan
Video Interview: Successful Pilot-Scale Run with Cayman Chemical Validates eXoZymes’ Technology and Scalability - The National Law Review
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Dr - The National Law Review
eXoZymes (NASDAQ:EXOZ) Shares Down 0.4%Should You Sell? - MarketBeat
Damien Alan Perriman Net Worth (2026) - GuruFocus
eXoZymes Advances Toward Planned Securities Offering Preparation - The Globe and Mail
Insider Sell: Tyler Korman Sells 1,500 Shares of EXoZymes Inc (E - GuruFocus
eXoZymes (EXOZ) files investor presentation tied to proposed securities offering - Stock Titan
eXoZymes CCO discusses NCTx spinout on podcast By Investing.com - Investing.com Australia
Exozymes (EXOZ) CSO logs small April open-market stock sales - Stock Titan
eXoZymes CCO discusses NCTx spinout on podcast - Investing.com
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast - ACCESS Newswire
Why eXoZymes spun out NCTx to take NCT down the supplement path - Stock Titan
Surprises Report: What are eXoZymes Incs recent SEC filings showing2026 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn
Exozymes Incannounces common stock offeringSEC filing - marketscreener.com
eXoZymes (NASDAQ: EXOZ) files prospectus for common stock offering with affiliated underwriter - Stock Titan
Pullback Watch: Is eXoZymes Inc backed by strong institutional buyingPortfolio Update Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
EXOZYMES (EXOZ) CCO awarded 146,437 options and 62,759 restricted shares - Stock Titan
EXOZYMES (NASDAQ: EXOZ) Chief Commercial Officer files initial Form 3 - Stock Titan
Insider Trends: Can eXoZymes Inc sustain earnings growthMarket Sentiment Review & Growth Oriented Trading Recommendations - baoquankhu1.vn
Latest EXOZ ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
EXOZ Technical Analysis & ETF Price Forecast - Intellectia AI
EXOZYMES (NASDAQ: EXOZ) CCO receives 8,887-share stock grant - Stock Titan
EXOZYMES (EXOZ) VP awarded 3,999 common shares as stock grant - Stock Titan
[Form 4] EXOZYMES INC. Insider Trading Activity - Stock Titan
Exozymes (EXOZ) CSO receives 5,332-share stock award - Stock Titan
Bond Watch: Is eXoZymes Inc a speculative investment2026 Price Swings & Detailed Earnings Play Strategies - baoquankhu1.vn
Does eXoZymes Inc stock have upside surprise potential2026 Fundamental Recap & Weekly Market Pulse Updates - baoquankhu1.vn
EXOZ PE Ratio & Valuation, Is EXOZ Overvalued - Intellectia AI
Nasdaq Moves: Is eXoZymes Inc forming a bullish divergenceShare Buyback & High Accuracy Buy Signal Tips - baoquankhu1.vn
Exozymes Inc Azioni (EXOZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exozymes Inc Azioni (EXOZ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Korman Tyler Paz | Chief Scientific Officer |
Apr 08 '26 |
Sale |
10.04 |
750 |
7,530 |
729,873 |
| Heltzen Michael | Chief Executive Officer |
Jul 02 '25 |
Buy |
10.22 |
1,040 |
10,629 |
10,629 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):